NR2A negative allosteric modulators (Novartis)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNR2A negative allosteric modulators (Novartis)
Drug Alias NameNR2A allosteric modulators (Mnemosyne)NR2A negative allosteric modulators (Mnemosyne)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate receptor ionotropic, NMDA 2A modulators
TargetsGlutamate receptor ionotropic, NMDA 2A
Therapy Area/IndicationsAutistic DisorderRett SyndromeNervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCadent Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsAutistic DisorderRett SyndromeNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A